American Association for Cancer Research
Browse
00085472can170298-sup-178280_2_supp_3972484_ll7cyt.png (49.49 kB)

Figure S2 from Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma

Download (49.49 kB)
figure
posted on 2023-03-31, 00:31 authored by Nidhi Jariwala, Devaraja Rajasekaran, Rachel G. Mendoza, Xue-Ning Shen, Ayesha Siddiq, Maaged A. Akiel, Chadia L. Robertson, Mark A. Subler, Jolene J. Windle, Paul B. Fisher, Arun J. Sanyal, Devanand Sarkar

Quantification of Western and IHC images

Funding

NCI

NIDDK

National Institute of Diabetes and Digestive and Kidney Diseases

NIH

History

ARTICLE ABSTRACT

SND1, a subunit of the miRNA regulatory complex RISC, has been implicated as an oncogene in hepatocellular carcinoma (HCC). In this study, we show that hepatocyte-specific SND1 transgenic mice (Alb/SND1 mice) develop spontaneous HCC with partial penetrance and exhibit more highly aggressive HCC induced by chemical carcinogenesis. Livers from Alb/SND1 mice exhibited a relative increase in inflammatory markers and spheroid-generating tumor-initiating cells (TIC). Mechanistic investigations defined roles for Akt and NF-κB signaling pathways in promoting TIC formation in Alb/SND1 mice. In human xenograft models of subcutaneous or orthotopic HCC, administration of the selective SND1 inhibitor 3′, 5′-deoxythymidine bisphosphate (pdTp), inhibited tumor formation without effects on body weight or liver function. Our work establishes an oncogenic role for SND1 in promoting TIC formation and highlights pdTp as a highly selective SND1 inhibitor as a candidate therapeutic lead to treat advanced HCC. Cancer Res; 77(12); 3306–16. ©2017 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC